secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-123809
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager selects lead candidate for SOD1-ALS gene therapy; IND filing expected mid-2025
--------------------------------------------------------------------------------

- Lead candidate combines siRNA construct with IV-delivered TRACER capsid targeting SOD1-mutated ALS.
- Non-human primate study showed 73% reduction of SOD1 in cervical spinal cord motor neurons after single IV dose.
- Another preclinical candidate previously increased survival by median 152 days in G93A mouse model.
- Additional candidate data to be presented at upcoming scientific conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923123809/0001104659-23-123809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923123809/tm2332263d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer